522-30-5 Usage
Description
Norsanguinarine is an organic compound that serves as an intermediate in the synthesis of Sanguinarium-13CD3 Chloride (S112502), which is the labeled analogue of Sanguinarium Chloride (S112500). Sanguinarium Chloride is a natural product known for its antimicrobial, anti-inflammatory, and antioxidant properties.
Uses
Used in Pharmaceutical Industry:
Norsanguinarine is used as an intermediate in the synthesis of Sanguinarium-13CD3 Chloride for its antimicrobial, anti-inflammatory, and antioxidant properties. This makes it a valuable compound in the development of new drugs and therapies targeting various health conditions.
Used in Research and Development:
Norsanguinarine is used as a research compound for studying the properties and potential applications of Sanguinarium Chloride and its labeled analogue, Sanguinarium-13CD3 Chloride. This helps scientists understand the mechanisms of action and potential benefits of these compounds in various fields, such as medicine, pharmacology, and biotechnology.
References
Furuya, Ikuta, Syono., Phytochem., 11,3041 (1972)
Check Digit Verification of cas no
The CAS Registry Mumber 522-30-5 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 5,2 and 2 respectively; the second part has 2 digits, 3 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 522-30:
(5*5)+(4*2)+(3*2)+(2*3)+(1*0)=45
45 % 10 = 5
So 522-30-5 is a valid CAS Registry Number.
InChI:InChI=1/C19H11NO4/c1-2-12-11-3-4-15-19(24-9-21-15)14(11)7-20-18(12)13-6-17-16(5-10(1)13)22-8-23-17/h1-7H,8-9H2
522-30-5Relevant articles and documents
The synthesis of sanguinarine.
Dyke,Moon,Sainsbury
, p. 3933 - 3934 (1968)
-
The synthesis and biological evaluation of sanguinarine derivatives as anti-non-small cell lung cancer agents
Ding, Ke,Jiang, Liang,Lu, Xiaoyun,Wang, Xiaolu,Wang, Yuting,Xu, Fang,Zhang, Zhang
, p. 293 - 296 (2020/04/17)
A novel series of sanguinarine (SA) derivatives were synthesized and evaluated as anti-non-small cell lung cancer (NSCLC) agents. The compounds inhibited A549 and H1975 NSCLC cells with IC50 values of 0.96->30 ΜM and 0.79->30 ΜM, respectively. Compounds 8d-8j exhibited low micromolar inhibitory activity and indicated that the C6-position of SA was tolerated to be substituted by hydrophilic groups and CN. Further investigation of their mechanism of action showed that compound 8h induced apoptosis of A549 and H1975 cells by inhibiting the Akt signaling pathway and elevating the reactive oxygen species (ROS). This study provided a strategy for developing new anti-cancer agents.
SANGUINARINE ANALOG PP2C INHIBITORS FOR CANCER TREATMENT
-
, (2014/10/03)
Sanguinarine analogs as PP2C inhibitors are disclosed for the treatment of various cancers, as well as methods of synthesizing such analogs.
